Abstract: Rhabdomyosarcoma (RMS) is a malignancy in the mesenchyme that shows differentiationof skeletal muscles, most commonly found in childhood to old age and can occur in any location throughout the body. PDL1 is an inhibiting molecule that causes disruption of the immune response against tumor cells. Revealed expression of PDL1 is associated with a poor prognosis. This study used tissue samples of rhabdomyosarcoma tumors to assess the association between immunohistochemical expressions of PDL1 and histopathology grade among rhabdomyosarcoma patients.